BackgroundFollowing the message that Gems will be discontinued on November 17, 2026, and automatically migrated to Skills, I ...
A twelve-week quasi-experimental study of 60 Saudi EFL university students found that Grammarly-supported process writing ...
Yeroen the chimpanzee was limping.However, whether it was his right leg or his left leg—that changed depending on who he was ...
A new theoretical paper argues that societies of interacting AI agents can form durable, system-level machine opinions that ...
Richard Socher, co-founder and CEO of Recursive, argues on the Peter Diamandis podcast that while weak forms of recursive self-improvement ...
Contemplating a future where machines break free of human meddling, with internet law expert Jonathan Zittrain.
Every year, the Nobel Prize in Literature drives contentious literary discourse about our most prestigious living writers.
New York Magazine on MSN
What Would You Do If Your Employer Could Destroy the World?
Exit interviews with defectors from OpenAI, Anthropic, and DeepMind.
Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund 6.56M Jun 30, 2026 1.22% 31,341,782 ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results